nih 3t3 mouse fibroblast cells  (ATCC)

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Effect of 10 Gy X‐ray on viability of NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells. Blue: untreated controls; Pink: irradiated cells. Cell counts were conducted at 24, 48, and 72 h post‐treatment. Statistical analysis was performed using two‐way ANOVA with Tukey's post hoc test: p < 0.05 (*), p < 0.005 (**), p < 0.0005 (***), p < 0.0001 (****), n = 3. Note: Y ‐axes are scaled independently for each cell line to account for differences in baseline growth, allowing clearer visualization of treatment effects. Tumor cell counts and representative images can be found in Appendix Table and Figure .

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques: Irradiation

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Images of untreated NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells and cells exposed to X‐ray. Scalebar: 300 µm.

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques:

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Viability of NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells after treatment with IMP‐1700 (5 µM), ciprofloxacin (CPX) (15 µM), their combination, or DMSO, with and without 10 Gy X‐ray. Cell counts were measured at 24, 48, and 72 h post‐treatment. Statistical significance assessed via two‐way ANOVA and Tukey's post hoc test: p < 0.05 (*), p < 0.005 (**), p < 0.0005 (***), p < 0.0001 (****), n = 3. Significant differences are only shown compared to untreated or 10 Gy. Tumor cell count values and images are available in Appendix Table and Figure , , , .

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques: Cell Characterization

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Images of NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells treated with IMP‐1700, with and without X‐ray. Scalebar: 300 µm.

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques:

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Images of NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells treated with ciprofloxacin (CPX), with and without X‐ray. Scalebar: 300 µm.

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques:

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Images of NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells treated with IMP‐1700 and ciprofloxacin (CPX), with and without X‐ray. Scalebar: 300 µm.

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques:

Journal: MicrobiologyOpen

Article Title: Synergistic Effects of IMP‐1700, Ciprofloxacin, and X‐Ray Radiation in Bacteria and Mammalian Cell Lines: Implications for Use in Antimicrobial‐Resistant Bacteria

doi: 10.1002/mbo3.70270

Figure Lengend Snippet: Images of NIH‐3T3, B16.F10, MDA‐MB‐231, and HepG2 cells treated with DMSO, with and without X‐ray. Scalebar: 300 µm.

Article Snippet: The tumor cell lines, mouse melanoma B16.F10 (CRL‐6475, ATCC), human breast cancer MB‐MDA‐231 (CRM‐HTB‐26, ATCC), human hepatocellular carcinoma HepG2 C3A (a derivative of HepG2, CRL‐3581, ATCC), as well as the noncancerous mouse fibroblast cell line NIH‐3T3 (CRL‐1658, ATCC), were cultivated at 37°C, 5% CO2.

Techniques:

Journal: Materials Today Bio

Article Title: Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG–lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis

doi: 10.1016/j.mtbio.2026.102884

Figure Lengend Snippet: Characterization and gene editing efficiency of PBAE-Plasmid NPs. ( a ) and ( b ) RNA silencing effects of different sgRNAs targeting JAK1 in NIH-3T3 and DC 2.4 cells. ( c ) Size and zeta potential of the PBAE-plasmid complex at various mass ratios. ( d ) Agarose gel electrophoresis of the PBAE/plasmid complex at different mass ratios. ( e ) Size distribution analyzed by dynamic light scattering (DLS) and transmission electron microscopy (TEM) images of PBAE-plasmid NPs at a mass ratio of 20:1. ( f ) and ( g ) Effects of the PBAE-plasmid complex at various mass ratios on NIH-3T3 and DC 2.4 cell viability. ( h ) Green fluorescence in NIH-3T3 cells transfected with PBAE-plasmid NPs. ( i ) JAK1 mRNA expression in NIH-3T3 cells transfected with PBAE-plasmid NPs. ( j ) JAK1 protein expression in mice transfected with PBAE-plasmid NPs. ( k ) Quantitative analysis of (j). Data are presented as mean ± SD (n = 3). Bars sharing the same letter are not significantly different, whereas those with different letters are statistically significant (p < 0.05).

Article Snippet: Mouse embryonic fibroblast NIH/3T3 cells and mouse dendritic DC2.4 cells were obtained from the American Type Culture Collection (ATCC).

Techniques: Plasmid Preparation, Zeta Potential Analyzer, Agarose Gel Electrophoresis, Transmission Assay, Electron Microscopy, Fluorescence, Transfection, Expressing